LSTANasdaqPharmaceutical PreparationsFiscal year ends December 31
LISATA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.00−0.03 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $9.11M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
-10711.2%
Net margin
-9756.5%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -83.0% | – | – | -38.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -228.4% | -30.6% | -74.7% | |
| Return on assets | -59.0% | -25.8% | -62.9% | |
| Current ratio | 1.16 | 10.08 | 5.76 | |
| Debt to equity | 1.16 | – | – | |
| Net debt to EBITDA | 0.05× | – | – | |
| Interest coverage | -16.6× | – | – | |
| Capex to revenue | 3.1% | – | 16.5% | |
| Diluted shares | 0M | 1M | 9M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Lisata Therapeutics generated $98.75M from operations and spent $373.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$98.75M
Used
$373.00K
Capital expenditure$373.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-9756.5%
×Asset turnover0.01×
×Equity multiplier1.19×
=Return on equity, FY2025-74.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -9756.5% | 0.01× | 1.19× | -74.7% |
| FY2024 | -1998.5% | 0.02× | 1.15× | -51.4% |
| FY2016 | -92.6% | 0.64× | 3.87× | -228.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$16.59M
- Cash generatingOperating cash flow above zero-$15.95M
- Return on assets improvedROA up on the prior year-36.5% → -47.4%
- Earnings backed by cashOperating cash flow above net income-$15.95M vs -$16.59M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.16 → 5.76
- No dilutionShare count did not rise8M → 9M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.02 → 0.00